Fc Fusion Therapeutics – A New Approach to Drug Therapy

Since the approval of Enbrel®, CD4-Fc fusion protein (for the treatment of rheumatoid arthritis) in 1998, Fc fusion therapies have evolved into a prominent class of therapeutics.[1] Currently, 13 Fc fusion drugs are commercially available, while around 50 molecules are under development for various disease indications. Some of the Fc fusion therapeutics including Arcalyst® (recurrent pericarditis, March 2021),[2] Reblozyl® (beta-thalassemia, September 2020)[3] and Alprolix® (haemophilia B, May 2016) were approved recently.[4] These molecules combine the beneficial pharmacological properties of biologically active ligands with the properties of the crystallizable fragment (Fc) domain of an immunoglobulin G (IgG).[5] Among the fusion proteins, several fragment crystallizable (Fc)-fusion therapeutics have been successfully treating various diseases, including autoimmune and inflammatory, cancer, infectious, cardiovascular and type 2 diabetes mellitus

Leave a Reply